Yapay Zeka Hızlı Bakış & Çıkarımlar
AI InsightBulgular: Serum ferritin düzeyi kontrol grubunda (grup 1) ortalama 60.60 nglml, non-metastatik kanserli hastalarda (grup 2) 59.55 nglmL olarak bulundu ve iki grup arasında anlamlı bir fark bulunamadı (p>0.9).
📌 3 Maddede Bu Makale
Özet
Amaç: Çalışmamızda metastazlı ve metastazsız meme kanserli kadınlarda demir (Fe), Total demir bağlama kapasitesi (TDBK), ferritin ve C-reaktif protein (CRP) düzeylerini araştırdık. Gereç ve Yöntem: Bu amaçla yaşları 30-77 arasında 20 metastazsız, 20 metastazlı, 40 meme kanserli kadın hasta ve 20 kişilik kontrol grubu, çalışmaya alındı. Ferritin, demir, TDBK seviyelerine Hitachi 717 otoanalizöründe, CRP düzeylerine nefelometrede bakıldı. Bulgular: Serum ferritin düzeyi kontrol grubunda (grup 1) ortalama 60.60 nglml, non-metastatik kanserli hastalarda (grup 2) 59.55 nglmL olarak bulundu ve iki grup arasında anlamlı bir fark bulunamadı (p>0.9). Buna karşılık, metastatik kanserli hastalarda (grup 3) 427.25 nglml olup, grup 3 ile grup 1 ve grup 2 arasında anlamlı bir fark bulundu (p 0, 9, p>0, 1). Serum TDBK düzeyi ortalama değeri grup l'de 302.15 fig/dl, grup 2'de 366.20 fig/dl olup iki grup arasında anlamlı bir fark bulundu (p 0.3) grup 3'te ise 42.25 mgll olup, grup 3 ile grup 1 ve grup 2 arasında anlamlı bir fark bulundu (p<0.001). Sonuçlar: Metastazlı hasta grubunda serum CRP, TDBK ve ferritin düzeylerinin kontrol ve non-metastatik hastalara göre daha anlamlı şekilde yükseldiğini bulduk.
Abstract
Objective: In this current study, we investigated the iron (FE), total iron binding capacity (TIBC), ferritin, and C-reactive protein (CRP) levels in breast cancer patients with and without metastasis. Study Design: To this aim, 40 breast cancer women, 20 with metastasis, 20 without metastasis, and a control group of 20 healthy women were included in the study. Ferritin, iron, and TIBC were measured in Hitachi 717 autoanalyser, and CRP levels were detected by nephelometric method. Results: The mean serum ferritin level was 60.60 nglml in control group (group 1), 59.55 nglml in non-metastatic patient group (group 2), and there was not any significant difference between this two groups (p>0.90). Contrarily, the mean ferritin level was 427.25 nglml in metastatic patient group (group 3), and this was significantly different from the means of group 1 and 2 (p<0.00I, p<0.001). Serum iron levels' means were respectively 65.75 fig/dl, 83.40 figldL, 66, 0 fig/dl in group 1,2, and 3. There was not any difference between group 3 versus group land 2 (p>0, 9, p>0,1). The mean serum TIBC level was 302.15 fig/dl in group 1 and 366.20 fig/dl in group 2, and there was a significant difference between two groups (p< 0.001). On the other hand, the mean TIBC level of group 3 was 312.75 fig/dl, and this was significantly different from group 2 (p<0.020) but did not show any difference from group 1 (p:0.3-05). The mean serum CRP level was 0.75 mgll in group 1, 2.20 mgll in group 2, and there was not any significant difference between two groups (p>0.3). This value was 42.25 mgll in group 3, and it vas significantly different from group 1 and2(p<0.001). Conclusions: We,found that serum CRP, TIBC, and ferritin values were significantly different in metastatic breast cancer patients than those of non-metastatic breast cancer patients and those of healthy control indivuduals.